121 related articles for article (PubMed ID: 25937263)
1. Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.
Miquel-Cases A; Steuten LM; Retèl VP; van Harten WH
Breast; 2015 Aug; 24(4):397-405. PubMed ID: 25937263
[TBL] [Abstract][Full Text] [Related]
2. Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis.
Miquel-Cases A; Retèl VP; van Harten WH; Steuten LM
Value Health; 2016 Jun; 19(4):419-30. PubMed ID: 27325334
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of tumor-infiltrating lymphocytes biomarkers guiding chemotherapy de-escalation in early triple-negative breast cancer.
Li S; Liu Y; Zhang P; Wang M; Sun L
Cancer Med; 2023 Nov; 12(22):21001-21012. PubMed ID: 37964682
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.
Li JB; Lin ZC; Wong MCS; Wang HHX; Li M; Li S
BMC Med; 2022 Sep; 20(1):320. PubMed ID: 36156186
[TBL] [Abstract][Full Text] [Related]
5. Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy.
Schouten PC; Marmé F; Aulmann S; Sinn HP; van Essen HF; Ylstra B; Hauptmann M; Schneeweiss A; Linn SC
Clin Cancer Res; 2015 Feb; 21(4):763-70. PubMed ID: 25480832
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
7. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of alternative treatments for depression in low-income women.
Beil H; Beeber LS; Schwartz TA; Lewis G
J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
Chisaki Y; Kuwada Y; Matsumura C; Yano Y
Clin Drug Investig; 2021 Apr; 41(4):381-389. PubMed ID: 33674955
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
11. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B
J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
14. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
16. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
17. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Candon D; Healy J; Crown J
Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
[TBL] [Abstract][Full Text] [Related]
18. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
19. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
Simoes Correa-Galendi J; Del Pilar Estevez Diz M; Stock S; Müller D
Appl Health Econ Health Policy; 2021 Jan; 19(1):97-109. PubMed ID: 32537695
[TBL] [Abstract][Full Text] [Related]
20. Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.
Miquel-Cases A; Retèl VP; Lederer B; von Minckwitz G; Steuten LM; van Harten WH
PLoS One; 2016; 11(4):e0154386. PubMed ID: 27124410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
